ARWR ARROWHEAD PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 879407 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.6%
TTM net income YoY-44,302.3%
TTM EPS YoY-51,000.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-156.9%
Net margin-160.6%
FCF margin-63.0%
EBITDA margin-151.4%
Returns
ROE-280.5%
ROA-46.4%
ROIC (approx.)-492.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets97.1%
Debt / equity0.00x
Current ratio4.14x
Interest coverage-7.55x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-29.0%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-09-30 | FY20252025-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $450.82M | $829.45M |
| R&D expense | $739.14M | $607.16M |
| SG&A expense | $202.04M | $123.94M |
| Operating income | -$707.17M | $98.35M |
| Interest expense | $93.71M | $89.36M |
| Pretax income | -$723.91M | $51.53M |
| Income tax | -$6.78M | $21.42M |
| Net income | -$724.21M | -$1.63M |
| EBITDA | -$682.47M | $120.55M |
| EPS (basic) | -5.11 | -0.01 |
| EPS (diluted) | -5.11 | -0.01 |
| Weighted avg. shares (diluted) | 141.63M | 133.76M |
| Balance sheet | ||
| Cash & equivalents | $62.73M | $226.55M |
| Short-term investments | $1.13B | $692.82M |
| Receivables | $9.93M | $6.82M |
| Inventory | $9.07M | $0 |
| Current assets | $1.29B | $950.64M |
| PP&E, net | $371.31M | $382.51M |
| Intangibles | $5.16M | $6.86M |
| Total assets | $1.74B | $1.39B |
| Current liabilities | $311.34M | $195.49M |
| Total liabilities | $1.69B | $881.88M |
| Shareholders' equity | $50.31M | $466.05M |
| Shares outstanding | 141.29M | 135.70M |
| Cash flow statement | ||
| Operating cash flow | -$271.95M | $179.55M |
| Capital expenditure | $11.99M | $22.67M |
| Free cash flow | -$283.94M | $156.89M |
| Investing cash flow | -$670.48M | -$129.29M |
| Financing cash flow | $776.82M | $74.01M |
| Depreciation & amortization | $24.70M | $22.20M |
| Stock-based compensation | $68.15M | $63.37M |
Free plan shows the latest 2 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.